FDAapproval83% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Pfizer.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · COVID-19 Vaccine
- Sub-indication
- General
Related signal: European Commission Approves Pfizer-BioNTech XFG-adapted COVID-19 Vaccine for 2026-2027